System for Identifying Connections Between Perturbagens and Genes Associated with a Skin Hyperpigmentation Condition

Abstract

A system for identifying connections between perturbagens and genes associated with a skin hyperpigmentation condition. The system includes a computer readable medium having a plurality of instances stored thereon, and a skin hyperpigmentation-relevant gene expression signature. Each instance includes an instance list of rank-ordered identifiers of differentially expressed genes, and the hyperpigmentation-relevant gene expression signature includes a gene expression signature list of identifiers representing differentially expressed genes associated with a hyperpigmentation condition or differentially expressed genes associated with a benchmark skin-lightening agent. The system also includes a programmable computer with computer-readable instructions that allow the computer to accessing the instances and a hyperpigmentation-relevant gene expression signature stored on the computer readable medium, comparing the hyperpigmentation-relevant gene expression signature to the plurality of the instances, and / or assigning a connectivity score to each of the plurality of instances.

Description

BACKGROUND OF THE INVENTION[0001]Skin pigment irregularities are common across ethnic and racial groups and are often considered cosmetically disfiguring. Disorders of pigment production and distribution occur as a function of intensity and duration of UV radiation exposure, life style habits, chronological age, endocrine functioning and disease state and are found ubiquitously in older populations. Hence there is a widespread demand for skin pigment modifying, skin lightening and skin tone enhancing products for the cosmetic market.[0002]The color of normal human skin is due primarily to varying amounts and distribution of melanin, hemoglobin, and carotenoids. Of these pigments, melanin is of primary significance to cosmetic skin treatment protocols. Melanin is produced by specialized cells in the skin called melanocytes through a complicated series of chemical and enzymatic reactions, mainly involving the copper and manganese containing enzyme tyrosinase. Once synthesized, the mel...

AI Technical Summary

Benefits of technology

The patent describes a new way to discover skin lightening agents that can help treat skin pigmentation disorders. This approach is called C-map and it can help researchers identify effective ingredients that can reduce skin darkness.

Problems solved by technology

A variety of skin hyperpigmentation disorders are known and etiology is diverse, overlapping in many cases, and often not fully understood.

Ideally treatment would restore lost pigmentation in vitiligo-affected skin, but this approach has met with little success via topical interventions and formulations.

Although cosmetic camouflage with dihydroxyacetone sunless-tanning lotions provides some darkening of hypo-pigmented areas, it also tends to darken surrounding normal skin, substantially maintaining the undesirable contrast.

Due to concerns over toxicity and carcinogenic effects, the United States limits treatment solutions to a 2% or lower concentration and the FDA has proposed a ban on all over-the-counter preparations, while hydroquinone is currently banned in Europe as a skin lightening or depigmenting agent.

Kojic acid, Azelaic acid and certain-hydroxy acids such as glycolic acid, have demonstrated skin-lightening effects, but reports of localized irritation and inflammation are common.

Skin pigmentation and the broader cosmetic concept of skin tone, are therefore highly complex conditions with multiple and overlapping etiologies, which manifest in part as a function of individual predisposition, and which therefore pose a significant treatment challenge.

Nonetheless, certain limiting presumptions challenge application of C-map with respect to diseases of polygenic origin or syndromic conditions characterized by diverse and often apparently unrelated cellular phenotypic manifestations.

According to Lamb, the challenge to constructing a useful C-map is in the selection of input reference data which permit generation of clinically salient and useful output upon query.

Theoretically this leads to heightened potential for in vitro to in vivo mismatch, and limits output information to the context of a particular cell line.

Cosmetic agents tend to be substantially non-specific with respect to effect on cellular phenotype, and administration to the body is generally limited to application on or close to the body surface.

In constructing C-maps relating to pharmaceutical agents, Lamb stresses that particular difficulty may be encountered if reference connections are extremely sensitive and at the same time difficult to detect (weak), and Lamb adopted compromises aimed at minimizing numerous, diffuse associations.

Cosmetic agents, therefore, provide more diverse and less acute effects on cellular phenotype and generate the sort of associations expressly taught by Lamb as unsuitable for generating connectivity maps useful for confident hypothesis testing.

Successful identification of skin lightening agents has proven to be difficult due to the multi-cellular, multi-factorial processes involved in etiology of the hyperpigmentation condition itself.

Such weak responses arise, in part, due to the great number of genes and gene products involved, and the fact that skin-active and cosmetic agents may affect multiple genes in multiple ways.

Moreover, the degree of bioactivity of cosmetic agents may differ for each gene and be difficult to quantify.

It is unclear whether statistically valid data may be generated from cosmetic C-maps and it is further unclear whether a cell line exists which may provide salient or detectable cosmetic data.

Images